RICERCA
AUTORI
RIVISTE
Sfoglia per AUTORE
BUTTIGLIERO C
Collezione ASL Asti
Items : 35
Safety profile of darolutamide versus placebo: a systematic review and meta-analysis. in Prostate cancer and prostatic diseases / Prostate Cancer Prostatic Dis. 2024 Sep;27(3):385-392. doi: 10.1038/s41391-023-00775-y. Epub 2023 De
2024
ASL Asti
AO Ordine Mauriziano
Di Maio M; Tucci M; Vogl UM; Buttigliero C; Tombal B; Cathomas R; Smith MR; Fizazi K; Treglia G; Turco F; Gillessen S;
Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2024 Oct;22(5):102138. doi: 10.1016/j.clgc.2024.102138. Epub 2024 Jun 12.
2024
ASL Asti
AOU San Luigi di Orbassano
AO Ordine Mauriziano
Tucci M; Scagliotti GV; Di Maio M; Palesandro E; Poletto S; Calabrese M; Saporita I; Crespi V; Farinea G; Di Stefano RF; Gallina A; Fossati N; Zilli T; Delcuratolo MD; Gillessen S; Turco F; Vogl UM; Buttigliero C;
Treatment options in first-line metastatic renal carcinoma: A meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trials. in Cancer treatment reviews / Cancer Treat Rev. 2024 Jun;127:102745. doi: 10.1016/j.ctrv.2024.102745. Epub 2024 Apr 27.
2024
ASL Asti
Munoz F; Muraro M; Singh N; Campisi I; Palesandro E; Turco F; Buttigliero C; Durante E; Giuliani J; Tucci M; Mandarà M; Fiorica F;
Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma. in Journal of clinical medicine / J Clin Med. 2024 Jan 5;13(2):307. doi: 10.3390/jcm13020307.
2024
ASL Asti
AOU San Luigi di Orbassano
Buttigliero C; Carfì FM; Tucci M; Calabrese M; Saporita I; Pisano C; Turco F; Delcuratolo MD; Di Stefano RF; Samuelly A;
Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis. in Cells / Cells. 2024 Aug 22;13(16):1396. doi: 10.3390/cells13161396.
2024
ASL Asti
AOU San Luigi di Orbassano
Tucci M; Di Stefano FR; Audisio M; Turco F; Delcuratolo MD; Poletto S; Saporita I; Carfì F; Calabrese M; Farinea G; Buttigliero C;
TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2024 Apr;22(2):56-67.e16. doi: 10.1016/j.clgc.2023.08.006. Epub 2023 Sep 7.
2024
ASL Città di Torino
AO Cuneo
ASL Asti
ASL Cuneo 2
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Filippi R; Brusa F; Prati V; Vana F; Mennitto A; Maio MD; Buttigliero C; Vignani F; Dionisio R; Icardi M; Guglielmini P; Buosi R; Stevani I; Vormola R; Numico G; Depetris I; Comandone A; Gennari A; Airoldi M; Rossi M; Vellani G; Ortega C; Ruatta F; Tucci M; Pisano C; Turco F; Arnaudo E; Fea E; Vanella P; et alii...
Maximal androgen blockade therapy (MAB) for prostate cancer (PC) and risk of bone fractures: A systematic literature review and meta-analysis in Journal of Clinical Oncology
2024
ASL Asti
Turco F; Saporita I; Calabrese M; Carfi FM; Mogavero A; Treglia G; Gillessen S; Di Maio M; Tucci M; ButtIgliero C; Vogl U;
Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2023 Jan;181:103881. doi: 10.1016/j.critrevonc.2022.103881. Epub 2022 Nov 24
2023
AO Ordine Mauriziano
ASL Asti
AOU San Luigi di Orbassano
Scagliotti GV; Buttigliero C; Di Maio M; Audisio A; Brusa F; Ungaro A; Audisio M; Samuelly A; Turco F; Di Stefano RF; Tucci M; Delcuratolo MD;
Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer. in International journal of molecular sciences / Int J Mol Sci. 2023 Dec 20;25(1):78. doi: 10.3390/ijms25010078.
2023
ASL Asti
AOU San Luigi di Orbassano
Farinea G; Poletto S; Carfì FM; Di Stefano RF; Vogl UM; Castro E; Gillessen S; Turco F; Saporita I; Calabrese M; Tucci M; Buttigliero C;
Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis. in Tumori / Tumori. 2023 Apr;109(2):233-243. doi: 10.1177/03008916221077144. Epub 2022 Mar 31.
2023
ASL Asti
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Buttigliero C; Di Maio M; Scagliotti GV; Ungaro A; Parlagreco E; Audisio A; Audisio M; Angusti T; Parente A; Di Stefano RF; Urban S; Pisano C; Samuelly A; Tucci M; Turco F;
How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy? in Research and reports in urology / Res Rep Urol. 2023 Jan 19;15:9-26. doi: 10.2147/RRU.S350793. eCollection 2023.
2023
ASL Asti
Di Stefano RF; Saporita I; Calabrese M; Cani M; Farinea G; Crespi V; De Filippis M; Poletto S; Pisano C; Di Prima L; Turco F; Tucci M; Buttigliero C;
Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine? in Cells / Cells. 2022 May 11;11(10):1614. doi: 10.3390/cells11101614.
2022
ASL Asti
Tucci M; Cani M; Farinea G; Crespi V; Di Prima L; Di Stefano RF; Parlagreco E; Pisano C; Delcuratolo MD; Turco F; Buttigliero C; Audisio M;
Darolutamide in Metastatic Prostate Cancer. in The New England journal of medicine / N Engl J Med. 2022 Jun 16;386(24):2344. doi: 10.1056/NEJMc2205310.
2022
ASL Asti
Buttigliero C; Turco F; Tucci M;
New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine? in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2022 Jun;174:103682. doi: 10.1016/j.critrevonc.2022.103682. Epub 2022 Apr 11
2022
ASL Asti
ASL Torino 4
ASL Cuneo 1
ASL Cuneo 2
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Buttigliero C; Scagliotti GV; Di Maio M; Ortega C; Di Prima L; Audisio A; Turco F; Ungaro A; Parlagreco E; Di Stefano RF; Audisio M; Tucci M;
New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond. in Cells / Cells. 2022 Jan 21;11(3):357. doi: 10.3390/cells11030357.
2022
ASL Asti
ASL Torino 4
AOU San Luigi di Orbassano
Tucci M; Di Prima L; Turco F; Di Stefano RF; Ungaro A; Audisio M; Parlagreco E; Delcuratolo MD; Audisio A; Buttigliero C;
Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside. in Cells / Cells. 2022 Feb 25;11(5):803. doi: 10.3390/cells11050803.
2022
ASL Asti
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Delcuratolo MD; Ungaro A; Buttigliero C; Di Maio M; Audisio A; Di Prima L; Turco F; Scagliotti GV; Pisano C; Tucci M;
Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis. in Current oncology (Toronto, Ont.) / Curr Oncol. 2022 Dec 4;29(12):9511-9524. doi: 10.3390/curroncol29120747.
2022
ASL Asti
Tucci M; Munoz F; Grigolato D; Muraro M; Turco F; Fiorica F; Buttigliero C;
Prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223: a retrospective study. in Minerva urology and nephrology / Minerva Urol Nephrol. 2022 Dec;74(6):703-713. doi: 10.23736/S2724-6051.22.04701-2. Epub 2022 Feb 11.
2022
ASL Asti
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Pisano C; DI Maio M; Tucci M; Scagliotti GV; Samuelly A; DI Stefano RF; Turco F; Bungaro M; Parente A; Buttigliero C; Angusti T;
Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapy. in Cancer communications (London, England) / Cancer Commun (Lond). 2022 Aug;42(8):683-688. doi: 10.1002/cac2.12340. Epub 2022 Jul 22.
2022
ASL Asti
ASL Cuneo 2
ASL Torino 4
ASL Cuneo 1
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Turco F; Ungaro A; Audisio M; Scagliotti GV; Di Maio M; Delcuratolo MD; Audisio A; Ortega C; Pisano C; Buttigliero C; Di Stefano RF; Tucci M;
Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate. in Prostate cancer and prostatic diseases / Prostate Cancer Prostatic Dis. 2021 Sep;24(3):812-825. doi: 10.1038/s41391-021-00336-1. Epub 2021 Fe
2021
ASL Asti
ASL Vercelli
AO Ordine Mauriziano
Di Maio M; Scagliotti GV; Gallicchio M; Vignani F; Pisano C; Bungaro M; Samuelly A; Turco F; Tucci M; Di Stefano RF; Buttigliero C;
Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Sep;155:127-135. doi: 10.1016/j.ejca.2021.06.034. Epub 2021 Aug 6.
2021
AO Cuneo
ASL Asti
ASL Biella
ASL Cuneo 2
AOU Città della Salute di Torino
ASL Città di Torino
AOU Novara
Tucci M; Baier S; Gennari A; Bellissimo AR; Ciccone G; Masini C; Sacco C; Amoroso D; Montagnani F; Comandone A; Ortega C; Buttigliero C; Fea E; Vanella P; Valcamonico F; Zamparini M; Sirotova Z; Chiappino I; Bianchi S; Mosca A; Dalla Volta A; Prati V; Dal Canton O; Berruti A;
Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC. in Endocrine-related cancer / Endocr Relat Cancer. 2021 Jun 2;28(7):R207-R216. doi: 10.1530/ERC-20-0457.
2021
ASL Asti
ASL Vercelli
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Buttigliero C; Di Maio M; Scagliotti GV; Pisano C; Audisio M; Samuelly A; Bungaro M; Tucci M; Di Stefano RF; Turco F;
Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2021 Jan;157:103185. doi: 10.1016/j.critrevonc.2020.103185. Epub 2020 Nov 27
2021
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli
AO Ordine Mauriziano
Buttigliero C; Di Maio M; Scagliotti GV; Di Stefano RF; Turco F; Tucci M; Pisano C;
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. in Minerva urology and nephrology / Minerva Urol Nephrol. 2021 Dec;73(6):803-814. doi: 10.23736/S2724-6051.21.04186-2. Epub 2021 Mar 29.
2021
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli
ASL Torino 4
AO Ordine Mauriziano
Buttigliero C; DI Maio M; Scagliotti GV; Tarenghi F; Vignani F; Bungaro M; Samuelly A; Turco F; DI Stefano RF; Tucci M; Pisano C;
Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report. in Tumori / Tumori. 2021 Dec;107(6):NP149-NP154. doi: 10.1177/03008916211059230. Epub 2021 Nov 11.
2021
ASL Asti
AOU San Luigi di Orbassano
Buttigliero C; Scagliotti GV; Bollito E; Bungaro M; Di Stefano RF; Samuelly A; Tucci M; Turco F;
Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough? in Minerva urology and nephrology / Minerva Urol Nephrol. 2021 Dec;73(6):870-872. doi: 10.23736/S2724-6051.21.04817-5.
2021
ASL Asti
ASL Torino 4
AOU San Luigi di Orbassano
Tucci M; Turco F; Buttigliero C;
Evaluation of Cognitive Function in Trials Testing New-Generation Hormonal Therapy in Patients with Prostate Cancer: A Systematic Review. in Cancers / Cancers (Basel). 2020 Sep 9;12(9):2568. doi: 10.3390/cancers12092568.
2020
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano
ASL Vercelli
Tucci M; Di Maio M; Necchi A; Gamba T; Buttigliero C; Vignani F; Marandino L;
On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2020 Oct;31(10):1415-1416. doi: 10.1016/j.annonc.2020.06.005. Epub 2020 Jun 18.
2020
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli
Zucali P; Tucci M; Verri E; Procopio G; Mucciarini C; Mosca A; Massari F; Fratino L; Masini C; Fornarini G; Ermacora P; Donini M; Buti S; Ceresoli GL; Bortolus R; Berruti A; Baldessari C; Buttigliero C; Zagonel V; Caffo O;
The prognostic value of pain in castration-sensitive prostate cancer. in Prostate cancer and prostatic diseases / Prostate Cancer Prostatic Dis. 2020 Dec;23(4):654-660. doi: 10.1038/s41391-020-0255-x. Epub 2020 Jul
2020
ASL Asti
ASL Vercelli
Milella M; Casadei C; Buttigliero C; Maines F; Pierantoni F; Bimbatti D; Mosillo C; Tucci M; De Giorgi U; Caffo O; Ciccarese C; Tortora G; Iacovelli R;
Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2020 Aug;152:102994. doi: 10.1016/j.critrevonc.2020.102994. Epub 2020 May 24
2020
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli
AO Ordine Mauriziano
Di Maio M; Tucci M; Scagliotti GV; Vignani F; Turco F; Tabbò F; Pisano C; Di Stefano RF; Buttigliero C; Leone G;
2020
ASL Biella
ASL Città di Torino
ASL Asti
AO Cuneo
ASL Cuneo 2
AOU Città della Salute di Torino
Fea E; Buttigliero C; Montagnani F; Comandone A; Gennari A; Tucci M; Chiappino I; Canton OD; Masini C; Sacco† C; Amoroso D; Sirotova Z; Ciccone G; Valcamonico F; Vanella P; Ortega C; Prati V; Bianchi S; Mosca A; Berruti A;
Evaluation of cognitive function (CogF) in trials testing new-generation hormonal treatments (NGHT) in patients with prostate cancer (PC): A systematic review in Annals of Oncology
2020
ASL Asti
Marandino L; Buttigliero C; Vignani F; Gamba T; Necchi A; Tucci M; Di Maio M;
Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways. in Cancer drug resistance (Alhambra, Calif.) / Cancer Drug Resist. 2020 Sep 12;3(4):726-741. doi: 10.20517/cdr.2020.42. eCollection 2020.
2020
ASL Asti
AOU San Luigi di Orbassano
Tucci M; Buttigliero C; Bungaro M;
Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents. in Endocrine / Endocrine. 2019 Jun;64(3):724-726. doi: 10.1007/s12020-019-01947-4. Epub 2019 May 7.
2019
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli
Berruti A; Vittorio Scagliotti G; Sigala S; Buttigliero C; Bedussi F; Dalla Volta A; Pia A; Ferrari L; Tucci M; Roca E;
Safety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): A network meta-analysis of randomized controlled trials (RCT) in Annals of Oncology
2019
ASL Asti
Altavilla A; Maio MD; Tucci M; Lolli C; Schepisi G; Buttigliero C; Vignani F; De Giorgi U;